Recent advancements in PARP inhibitors-based targeted cancer therapy

Poly(ADP-ribose) polymerase inhibitors (PARPi) are a new class of agents with unparalleled clinical achievement for driving synthetic lethality in BRCA-deficient cancers. Recent FDA approval of PARPi has motivated clinical trials centered around the optimization of PARPi-associated therapies in a va...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Ping, Wang, Justin, Mishail, Daniel, Wang, Cun-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501589/
https://www.ncbi.nlm.nih.gov/pubmed/32983586
http://dx.doi.org/10.1093/pcmedi/pbaa030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501589/
https://www.ncbi.nlm.nih.gov/pubmed/32983586
http://dx.doi.org/10.1093/pcmedi/pbaa030

Ejemplares similares